Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02638766 |
|
Recruitment Status :
Completed
First Posted : December 23, 2015
Last Update Posted : March 27, 2023
|
Sponsor:
Grupo Espanol de Investigacion en Sarcomas
Collaborator:
Bayer
Information provided by (Responsible Party):
Grupo Espanol de Investigacion en Sarcomas
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | August 31, 2021 |
| Actual Study Completion Date : | August 31, 2021 |